Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
作者信息
Kutsch Nadine, Pallasch Christian, Tausch Eugen, Böhme Volkmar, Ritgen Matthias, Liersch Rüdiger, Wacker Alexander, Jacobs Georg, Trappe Ralf Ulrich, Dreger Peter, Fischer Kirsten, Fink Anna-Maria, Stilgenbauer Stephan, Zhai Shuyan, Li Biao, Jürgensmeier Juliane M, Rajakumaraswamy Nishanthan, Bhargava Pankaj, Hallek Michael, Eichhorst Barbara F
机构信息
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
出版信息
Hemasphere. 2022 Mar 8;6(4):e692. doi: 10.1097/HS9.0000000000000692. eCollection 2022 Apr.
Abstract
摘要
相似文献
1
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.替拉布替尼与恩托司泼替尼联合使用或不联合奥妥珠单抗治疗复发慢性淋巴细胞白血病的疗效和安全性
Hemasphere. 2022 Mar 8;6(4):e692. doi: 10.1097/HS9.0000000000000692. eCollection 2022 Apr.
2
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.替拉鲁替尼联合伊德拉利西布或恩特索利替尼治疗既往治疗的慢性淋巴细胞白血病的 Ib 期研究。
Clin Cancer Res. 2020 Jun 15;26(12):2810-2818. doi: 10.1158/1078-0432.CCR-19-3504. Epub 2020 Mar 10.
3
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.替拉鲁替尼与idelalisib联合或不联合奥妥珠单抗治疗复发慢性淋巴细胞白血病的疗效和安全性
Hemasphere. 2022 May 25;6(6):e729. doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun.
4
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.SYK 抑制剂 entospletinib 联合 obinutuzumab 对慢性淋巴细胞白血病患者的促凋亡和免疫调节作用。
Br J Clin Pharmacol. 2022 Feb;88(2):836-841. doi: 10.1111/bcp.14962. Epub 2021 Jul 19.
5
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.恩托司替尼与奥滨尤妥珠单抗用于复发/难治性慢性淋巴细胞白血病和B细胞恶性肿瘤患者的研究
Haematologica. 2021 Jul 1;106(7):2022-2025. doi: 10.3324/haematol.2020.270298.
6
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.在日本，复发或难治性 B 细胞恶性肿瘤患者中进行替拉鲁替尼（ONO-4059/GS-4059）的 I 期研究。
Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28.
7
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.苯达莫司汀后继奥滨尤妥珠单抗和维奈克拉治疗慢性淋巴细胞白血病（CLL2-BAG）：多中心、开放标签、2 期试验的主要终点分析。
Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.
8
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.在 IIIb 期 GREEN 研究中，奥滨尤妥珠单抗单药或联合化疗治疗未经治疗或复发/难治性慢性淋巴细胞白血病的安全性。
Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5.
9
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.替拉鲁替尼的长期安全性特征：在复发或难治性 B 细胞恶性肿瘤患者中进行的一项日本 I 期研究的最终结果。
Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28.
10
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia.奥妥珠单抗再治疗：慢性淋巴细胞白血病治疗领域的新补充。
SAGE Open Med Case Rep. 2019 Jan 16;7:2050313X18823917. doi: 10.1177/2050313X18823917. eCollection 2019.
引用本文的文献
1
Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis.复发/难治性慢性淋巴细胞白血病中新型靶向疗法的比较安全性：一项网状Meta分析
Ther Adv Med Oncol. 2024 Oct 9;16:17588359241285988. doi: 10.1177/17588359241285988. eCollection 2024.
2
Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.复发/难治性慢性淋巴细胞白血病新型靶向治疗的网络荟萃分析
Ther Adv Med Oncol. 2024 Jul 31;16:17588359241263710. doi: 10.1177/17588359241263710. eCollection 2024.
3
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.依地鲁赛布治疗慢性淋巴细胞白血病患者——来自德国慢性淋巴细胞白血病研究组注册登记处的真实世界数据。
Ann Hematol. 2023 Nov;102(11):3083-3090. doi: 10.1007/s00277-023-05314-2. Epub 2023 Jun 26.
4
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.慢性淋巴细胞白血病中的下一代布鲁顿酪氨酸激酶抑制剂：不断演变的挑战与新机遇
Cancers (Basel). 2023 Feb 27;15(5):1504. doi: 10.3390/cancers15051504.
5
Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib.用替拉布替尼成功治疗抗髓鞘相关糖蛋白神经病。
Heliyon. 2022 Oct 5;8(10):e10928. doi: 10.1016/j.heliyon.2022.e10928. eCollection 2022 Oct.
6
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.BTK 抑制剂在血液系统恶性肿瘤和炎症性疾病治疗中的作用机制及临床研究。
J Hematol Oncol. 2022 Oct 1;15(1):138. doi: 10.1186/s13045-022-01353-w.
7
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.奥滨尤妥珠单抗-地辛汀偶联物联合内体逃逸增强剂 SO1861 改善 B 细胞非霍奇金淋巴瘤的治疗。
Toxins (Basel). 2022 Jul 13;14(7):478. doi: 10.3390/toxins14070478.
本文引用的文献
1
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.苯达莫司汀、奥滨尤妥珠单抗（GA101）和伊布替尼序贯治疗慢性淋巴细胞白血病（CLL）：CLL2 - BIG试验的最终结果
Leukemia. 2022 Aug;36(8):2125-2128. doi: 10.1038/s41375-022-01629-7. Epub 2022 Jun 25.
2
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.泽布替尼（BGB-3111）联合奥妥珠单抗治疗慢性淋巴细胞白血病和滤泡性淋巴瘤患者。
Blood Adv. 2020 Oct 13;4(19):4802-4811. doi: 10.1182/bloodadvances.2020002183.
3
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
4
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.替拉鲁替尼联合伊德拉利西布或恩特索利替尼治疗既往治疗的慢性淋巴细胞白血病的 Ib 期研究。
Clin Cancer Res. 2020 Jun 15;26(12):2810-2818. doi: 10.1158/1078-0432.CCR-19-3504. Epub 2020 Mar 10.
5
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.阿卡拉布替尼联合奥滨尤妥珠单抗治疗初治及复发/难治性慢性淋巴细胞白血病
Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8.
6
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
7
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.伊布替尼联合维奈托克治疗复发/难治性慢性淋巴细胞白血病：CLARITY 研究。
J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.
8
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.依鲁替尼单药治疗既往接受 B 细胞受体抑制剂治疗的复发或难治性慢性淋巴细胞白血病患者：一项 2 期研究结果。
Leuk Lymphoma. 2019 Aug;60(8):1972-1977. doi: 10.1080/10428194.2018.1562180. Epub 2019 Jan 11.
9
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.CLL2-BIG：苯达莫司汀、伊布替尼和奥滨尤妥珠单抗（GA101）序贯治疗慢性淋巴细胞白血病。
Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.
10
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.伊布替尼治疗慢性淋巴细胞白血病患者完全缓解的预后因素：2 项临床试验的汇总分析。
JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.
Zotero 插件